Sequence Group C for Endocervical Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Arkansas for Medical Sciences, Little Rock, AR
Endocervical Cancer
The Oculus Quest 2 Virtual Reality Headset - Device
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

The primary objective is to demonstrate the feasibility of incorporating VR distraction into the brachytherapy and radiotherapy clinical workflow. The secondary objective is to determine if VR distraction during brachytherapy treatment for cervical cancer improves subjects' satisfaction, procedural/acute pain, and need for analgesics or anxiolytics.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 5 Secondary · Reporting Duration: 3 weeks

3 weeks
Benzodiazepine dose
Determination of VR distraction during brachytherapy treatment for cervical cancer improves subjects' satisfaction, procedural/acute pain, and need for analgesics or anxiolytics.
Determination of VR distraction during brachytherapy treatment for cervical cancer on anxiety
Determination of VR distraction during brachytherapy treatment for cervical cancer pain
Feasibility of incorporating VR distraction into the brachytherapy and radiotherapy clinical workflow
Opiod dose
The number of eligible subjects who enroll onto the study.
The number of subjects who successfully complete the study questionnaires for satisfaction, procedural pain, and anxiety.
The number of subjects who withdraw or are withdrawn from the study.
The number of times a technical problem occurs with the VR distraction

Trial Safety

Safety Progress

1 of 3

Trial Design

4 Treatment Groups

Sequence Group C
1 of 4
Sequence Group D
1 of 4
Sequence Group B
1 of 4
Sequence Group A
1 of 4
Experimental Treatment

20 Total Participants · 4 Treatment Groups

Primary Treatment: Sequence Group C · No Placebo Group · N/A

Sequence Group C
Device
Experimental Group · 1 Intervention: The Oculus Quest 2 Virtual Reality Headset · Intervention Types: Device
Sequence Group D
Device
Experimental Group · 1 Intervention: The Oculus Quest 2 Virtual Reality Headset · Intervention Types: Device
Sequence Group B
Device
Experimental Group · 1 Intervention: The Oculus Quest 2 Virtual Reality Headset · Intervention Types: Device
Sequence Group A
Device
Experimental Group · 1 Intervention: The Oculus Quest 2 Virtual Reality Headset · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 weeks
Closest Location: University of Arkansas for Medical Sciences · Little Rock, AR
Photo of Little Rock  1Photo of Little Rock  2Photo of Little Rock  3
2011First Recorded Clinical Trial
1 TrialsResearching Endocervical Cancer
444 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are female and are 18 years of age or older.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.